According to Vision Research Reports, the global primary immunodeficiency market size surpassed at US$ 6.56 Bn in 2021 and is expected to grow at a CAGR of 6.2% from 2022 to 2030.
According to Vision Research Reports, the global primary immunodeficiency market size surpassed at US$ 6.56 Bn in 2021 and is expected to grow at a CAGR of 6.2% from 2022 to 2030.
Global primary immunodeficiency market size is expected to reach US$ 11.27 billion by 2030,high prevalence of hypertension is anticipated to drive the global primary immunodeficiency market in the near future.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/36249
The market growth can be primarily attributed to a host of factors, including advancements in molecular studies, rapid strides taken by next-generation sequencing technologies, DNA sequencing, and RNA sequencing. Research and development activities will continue to play a key role in boosting the prospects of the new primary immunodeficiency treatment and therapies. Companies operating in the current market landscape should ideally focus on the development of tailor-made primary immunodeficiency therapies to gain an edge.
The primary immunodeficiency disorders (PIDs) are clinically heterogeneous disorders, the majority of which arise from genetic defects in immunologically relevant genes. Primary immune deficiencies are present in a heterogeneous manner, and a high index of suspicion is required to diagnose primary immune deficiencies. Any patient with a suspected or proven primary immunodeficiency disorder (PID) should be referred to the care of a clinical immunologist. Immune dysregulation phenotypes of PID are commonplace and include multiorgan autoimmunity, malignancy (particularly hematological), and autoinflammatory pathology such as periodic fever syndromes.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 6.56 billion |
| Revenue Forecast by 2030 | USD 11.27 billion |
| Growth rate from 2022 to 2030 | CAGR of 6.2% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, Treatment type, Region |
| Companies Covered | Shire plc, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A, Octapharma, China Biologic Products Holdings, Inc, Biotest AG, Sanquin, LFB SA |
Advancements in Genetic Management and Next-generation Sequencing Technologies to Aid Market Growth
One of the most common symptomatic primary immunodeficiency disorders that continues to attract investments and research include the common variable immunodeficiency disorder. The onset of genome sequencing and soaring interest in genome-wide association studies have played a key role in enhancing and understanding the overall genetics of common variable primary immunodeficiency. Research has also opened up new frontiers as far as understanding the pathogenesis of common variable primary immunodeficiency. In recent times, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is on the rise to assess common variable primary immunodeficiency that is linked with disease pathways and other therapeutic targets. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency.
The prevalence of primary immunodeficiency around the world is on the rise due to which, the demand for novel treatments and therapies has witnessed considerable growth. Significant progress in sequencing technologies is triggered by the discovery of a range of monogenic forms of common variable primary immunodeficiency. Over the past decade, due to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the common variable primary immunodeficiency space.
Advancements in Molecular Techniques Open up New Treatment Alternatives for Primary Immunodeficiency Disorders
Over the past few decades, inborn errors of immunity (IEIs) have witnessed exponential growth. In addition, over 400 glaring defects have been listed in the recently amended International Union of Immunological Societies (IUIS). In the past few years, due to considerable information pertaining to new genes and diseases, the primary immunodeficiency market is set to witness notable development and likely to emphasize on the concept of “inborn errors of immunity” as a collective group of various phenotypes such as infection, autoimmunity, autoinflammation, malignancy, allergy, etc. Developments in molecular studies have streamlined the detection of an array of potential targets for certain therapeutic interventions. Targeted therapies constitute small molecules and monoclonal antibodies, including cytokine inhibitors and cytokines. Some of the most popular and extensively used targeted therapies include rituximab— a therapy deployed to cater to issues related to autoimmune and lymph proliferative manifestations. Apart from noteworthy developments in molecular studies, gene therapies have also gained a great amount of popularity over the past three decades. The adoption of gene therapy in the primary immunodeficiency market has increased at a consistent pace since the 1990s, particularly to address X-SCID and ADA-SCID.
Although developments in molecular studies are expected to augment the market for primary immunodeficiency, companies in the current market landscape are expected to overcome a few major roadblocks, including increasing the availability of different diagnostic tools and treatments to patients across the world and offering customized treatments cost-effectively.
In terms of type, the global primary immunodeficiency market has been segmented into antibody deficiency, cellular deficiency, and innate immune. Antibody deficiency has been categorized into agammaglobulinaemia, common variable immune deficiency, selective IgA deficiency, IgG subclass deficiency, and others. Cellular deficiency has been classified into Ataxia Telangiectasia, hyper IgM syndromes, Wiskott-Aldrich syndrome, DiGeorge syndrome, and others. Innate immune has been split into complement deficiencies, hyper IgE syndrome, and others. The antibody deficiency segment captured the largest market share in 2019. The segment is expected to expand at the highest CAGR during the forecast period, owing to rise in need and demand for diagnosis by patients.
Based on treatment type, the global primary immunodeficiency market has been divided into immunoglobuline replacement therapy, antibiotic therapy, stem cell and gene therapy, and others (vaccines, nutritional supplements, and others). The immunoglobuline replacement therapy segment captured the largest market share in 2019. The segment is expected to expand at the highest CAGR during the forecast period due to increase in need and demand for diagnosis by patients.
Prominent Regions
North America held a major share of the global primary immunodeficiency market in 2019. Highly structured healthcare industry, presence of key players, and growth strategies of these players are the major factors driving the market in the region. Rise in awareness about benefits of procedures and increase in healthcare expenditure also contribute to the growth of the market in North America. Asia Pacific held the second largest share of the global primary immunodeficiency market in 2019. Growth of the primary immunodeficiency market in the region can be attributed to rise in prevalence of chronic diseases and well-developed health care sector in the region. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in the number of people with cardiovascular diseases, product approvals, and rise in awareness about cardiovascular diseases which ultimately lead to regular checkup and diagnosis, are factors anticipated to fuel the growth of the primary immunodeficiency market in the region.
Prominent players operating in the global primary immunodeficiency market include
- Shire plc
- CSL Behring
- Kedrion Biopharma Inc
- Grifols, S.A
- Octapharma
- China Biologic Products Holdings, Inc
- Biotest AG,
- Sanquin,
- LFB SA
Market Segmentation
By Type
- Antibody Deficiency
- Agammaglobulinaemia
- Common Variable Immune Deficiency
- Selective IgA Deficiency
- IgG Subclass Deficiency
- Others
- Cellular Deficiency
- Ataxia Telangiectasia
- Hyper IgM Syndromes
- Wiskott-Aldrich Syndrome
- DiGeorge Syndrome
- Others
- Innate Immune
- Complement Deficiencies
- Hyper IgE Syndrome
- Others
By Treatment type
- Immunoglobuline Replacement Therapy
- Antibiotic Therapy
- Stem cell and Gene Therapy
- Others (Vaccines, Nutritional Supplements, and Others)
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36249
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/